Gene And Cell Therapy Bottlenecks Will Pressure Margins Yet Eventually Support A Healthier Outlook

Catalysts

About Abeona Therapeutics

Abeona Therapeutics focuses on gene and cell therapies for rare diseases, including recessive dystrophic epidermolysis bullosa, using autologous cell based approaches.

What are the underlying business or industry changes driving this perspective?

• Although ZEVASKYN has broad commercial and government coverage across major commercial plans and all 51 Medicaid programs plus Puerto Rico, the need for complex prior authorization processes and financial agreements between payers and treatment centers could slow treatment ramp and delay revenue recognition, as revenue is only booked when product is applied.
• While the pool of identified and motivated RDEB patients at qualified treatment centers has more than doubled and referrals from non QTC sites are building, the multi step journey from identification to ZEVASKYN product order forms, biopsy, manufacturing and administration may limit near term treatment volumes and keep earnings and net margins under pressure.
• Although the expanding network of qualified treatment centers and interest from additional EB centers suggest a broader future footprint, variability in site onboarding, financial constraints at some centers and differing trade policies can cap capacity growth and slow the conversion of patient demand into revenue.
• While the company holds US$207.5 million in cash, cash equivalents, restricted cash and short term investments that is expected to fund over 2 years of operations without ZEVASKYN revenue, the need to sustain higher SG&A tied to the commercial buildout could weigh on operating leverage and delay improvement in net margins if treatment volumes ramp more slowly than planned.
• Although participation of the AB0503 gene therapy program in the FDA Rare Disease Endpoint Advancement pilot offers a structured path for endpoint development in ophthalmology, the additional regulatory work and clinical execution required introduce timing and cost uncertainties that may affect future R&D spending and push out any potential contribution to revenue and earnings.

Assumptions

This narrative explores a more pessimistic perspective on Abeona Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Abeona Therapeutics's revenue will grow by 768.6% annually over the next 3 years.
• The bearish analysts assume that profit margins will shrink from 20587.5% today to 28.9% in 3 years time.
• The bearish analysts expect earnings to reach $75.7 million (and earnings per share of $1.11) by about January 2029, down from $82.3 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $95.7 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 15.1x on those 2029 earnings, up from 3.4x today. This future PE is lower than the current PE for the US Biotechs industry at 21.1x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.19%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The multi step treatment journey for ZEVASKYN from identification and counseling through prior authorization, financial clearance, biopsy, manufacturing and final administration could remain slow, so revenue might build more gradually than hoped and keep earnings and net margins under pressure for longer.
• The company is carrying higher SG&A at US$19.3 million for the quarter to support the commercial buildout while R&D has shifted partly into inventory and SG&A, and if ZEVASKYN volumes do not scale to match this cost base quickly, profitability targets could slip and net margins could remain weak despite the current US$207.5 million cash balance.
• Regulatory and technical complexity in personalized gene and cell therapy manufacturing, highlighted by the rapid sterility assay issue that forced rejection of a full drug lot and a temporary biopsy pause, may lead to further quality interventions or plant maintenance shutdowns that constrain capacity, delay treatments and affect recognized revenue.
• Although broad commercial and Medicaid coverage is in place and a permanent J code starts in 2026, differences in payer policies, prior authorization criteria and financial agreements with treatment centers could still limit real world access in the long term, capping addressable patient throughput and affecting revenue and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Abeona Therapeutics is $14.0, which represents up to two standard deviations below the consensus price target of $20.64. This valuation is based on what can be assumed as the expectations of Abeona Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $28.0, and the most bearish reporting a price target of just $14.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $262.1 million, earnings will come to $75.7 million, and it would be trading on a PE ratio of 15.1x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of $5.22, the analyst price target of $14.0 is 62.7% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.